WHO joins agencies in beefing up inspections of API facilities

The World Health Organization (WHO) is joining an effort to extend the reach of regulatory inspections of API facilities and reduce duplication by sharing resources, InPharm reports. The effort was started by the US, Europe and Australia, allowing each to rely on inspections by the others to better use existing resources. The FDA, EMA and the Australian Therapeutic Goods Administration (TGA) can accept a report, ask regulators of one of the participants to expand an inspection or they can hold joint inspections. A recent report on the effort noted the WHO has joined through its Prequalification of Medicines program and that other entities agreeing to the requirements also may be allowed to participate. Story | Report

Suggested Articles

Recipharm has been building its capabilities in sterile injectable and inhalation drugs. Now it is buying a CDMO that manufactures devices for both.

The FDA has slapped the parent of Dollar Tree stores with a warning letter saying some CMOs that made its OTC products were among the world's worst.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.